4958-02-5Relevant articles and documents
MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
-
Paragraph 0373; 0374, (2019/10/15)
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
-
Page/Page column 24; 51; 52, (2017/10/13)
The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS
-
Page/Page column 44, (2011/12/02)
Heteroaryloxycarbocyclyl compounds of formula (I), and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive -compulsive disorder, and the like. Formula (I)
NOVEL INTERMEDIATES AND THEIR USE
-
Page/Page column 17, (2010/11/27)
The invention is directed to novel acyloxy imidazole intermediates useful for making certain C- 14 oxycarbonyl carbamate pleuromutilin derivatives. The invention is further directed to a process for making such acyloxy imidazole intermediates and to a pro
NEW PLEUROMUTILIN DERIVATIVE AND ITS USE
-
Page/Page column 12, (2010/11/27)
The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-ethenyl-3-hydroxy-2,4,7, 14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.
A concise synthesis of a novel insulin-like growth factor i receptor (IGF-IR) inhibitor
Slade, Joel,Bajwa, Joginder,Liu, Hui,Parker, David,Vivelo, James,Chen, Guang-Pei,Calienni, John,Villhauer, Edwin,Prasad, Kapa,Repic, Oljan,Blacklock, Thomas J.
, p. 825 - 835 (2012/12/30)
An efficient synthesis of a potent insulin-like growth factor I receptor (IGF-IR) inhibitor AEW541 (1) is described. The key step in the synthesis is the cis-selective reductive animation of cyclobutanone, which sets up the desired 1,3-stereochemistry of the cyclobutane ring. The amino group thus generated is used as a handle to build the pyrrolopyrimidine ring. The final step resulting in 1 is accomplished by alkylation of in situ generated mesylate with azetidine.
IMIDAZOPYRIDINE COMPOUND
-
Page/Page column 56, (2008/06/13)
The present invention provides an imidazopyridine compound represented by formula (I), wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.
Hydroxymethyl cyclobutyl purines
-
, (2008/06/13)
Antiviral activity is exhibited by compounds having the formula STR1 and their pharmaceutically acceptable salts. R1 is STR2 R2 is hydrogen, --PO3 H2, STR3 wherein R3 is hydrogen, alkyl, substituted a
